Coya Therapeutics (NASDAQ:COYA) Shares Up 0.2% – Should You Buy?

Coya Therapeutics, Inc. (NASDAQ:COYA)’s stock price traded up 0.2% during mid-day trading on Thursday . The company traded as high as $4.43 and last traded at $4.38. 240,962 shares traded hands during mid-day trading, a decline of 10% from the average daily volume of 267,532 shares. The stock had previously closed at $4.37.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on COYA. Roth Capital started coverage on Coya Therapeutics in a research report on Friday, June 5th. They set a “buy” rating and a $12.00 target price for the company. Wall Street Zen downgraded shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Friday, July 17th. Chardan Capital restated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Friday, June 12th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Coya Therapeutics in a research report on Friday, April 10th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Coya Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $15.33.

Coya Therapeutics Stock Up 0.2%

The firm has a market capitalization of $102.75 million, a PE ratio of -3.81 and a beta of 0.51. The stock has a 50-day simple moving average of $4.97 and a 200-day simple moving average of $4.70.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. The firm had revenue of $0.25 million for the quarter, compared to analysts’ expectations of $0.15 million. Coya Therapeutics had a negative return on equity of 55.86% and a negative net margin of 266.10%. Equities analysts forecast that Coya Therapeutics, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Coya Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. bought a new position in Coya Therapeutics during the fourth quarter worth about $4,640,000. AWM Investment Company Inc. bought a new stake in shares of Coya Therapeutics in the fourth quarter valued at approximately $4,205,000. CM Management LLC raised its position in shares of Coya Therapeutics by 16.7% in the fourth quarter. CM Management LLC now owns 350,000 shares of the company’s stock valued at $2,030,000 after purchasing an additional 50,000 shares during the period. Private Management Group Inc. bought a new stake in shares of Coya Therapeutics in the fourth quarter valued at approximately $1,626,000. Finally, Marshall Wace LLP lifted its stake in shares of Coya Therapeutics by 438.8% during the 4th quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock valued at $1,307,000 after buying an additional 183,533 shares in the last quarter. 39.75% of the stock is owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.